Cerecor Stock Price

0.135 (6.05%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cerecor Inc CERC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.135 6.05% 2.365 13:49:32
Open Price Low Price High Price Close Price Prev Close
2.18 2.17 2.385 2.23
Bid Price Ask Price Spread News
2.36 2.37 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,641 559,886 $ 2.31 $ 1,293,538 3,106,090 1.98 - 4.50
Last Trade Time Type Quantity Stock Price Currency
13:51:10 100 $ 2.365 USD

Cerecor Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 228.73M 96.71M 55.45M $ 6.70M $ - -0.88 -2.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 5.63M 2.80%

more financials information »

Cerecor News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CERC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.903.302.062.5815,362,501-0.535-18.45%
1 Month2.473.302.062.614,197,895-0.105-4.25%
3 Months3.854.152.062.721,821,587-1.49-38.57%
6 Months2.324.502.062.841,345,3540.0451.94%
1 Year2.404.501.982.79910,558-0.035-1.46%
3 Years3.887.64991.54763.03370,759-1.52-39.05%
5 Years3.387.64990.34012.52374,508-1.02-30.03%

Cerecor Description

Cerecor Inc is a biopharmaceutical company focused on development and commercialization of treatments for rare and orphan diseases. Its rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. It is also developing two monoclonal antibodies, CERC-002 and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for the treatment of severe pediatric-onset Crohn's disease and COVID-19 acute respiratory distress syndrome.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.